| | Case number | Age | Involvement | Immunohistochemistry staining | Treatment | Follow-up | Ref | | Gender |
| | 1 | 66 F | Waldeyer ring
Tonsil
Pharyngeal wall
Lingual tonsil
Nasal cavity | MCL: CD5+, CD20+, IgD+, cyclinD1+, Bcl-2+, CD3−
FL: CD2+, CD10+, Bcl-2+, Bcl-6+, CD5− | Corticosteroid | PET scan every 3–6 months | [2] |
| | 2 | M | Ocular adnexa | NA | NA | Poor prognosis mentioned | [3] |
| | 3 | 84 F | Spleen | FL: CD20+, CD23+, Bcl-6+, CD5−, CD43−, Bcl-2−
MCL: cyclinD1+, CD5− | Splenectomy
Patient refused additional treatment | 9 months after splenectomy, CT scan showed intra-abdominal lymphadenopathy and patient died from unknown cause 13 months later | [4] |
| | 4 | 70 F | Cervical LN
Inguinal LN | CD20+, CD3−, cyclinD1−
50% of B-cell expressed CD5 (MCL)
30% of B-cell expressed CD10 (FL) | No chemotherapy | CT of chest and abdomen showed no evidence of lymphadenopathy or hepatosplenomegaly | [5] |
| | 5 | 65 M | Inguinal LN | FL: CD20+, CD79a+, CD10+, Bcl-2+, CD5−, CD230, cyclinD1−, p27+
MCL: CD20+, CD79a+, CD5+, CD10−, CD23−, cyclinD1+, p27−
Interfollicular areas mostly CD5+ showing distinct cylinD1 staining | Splenectomy | MCL caused disease progression into spleen. One year after splenectomy, it achieved stable disease | [6] |
| | 6 | 58 F | Mesenteric LN
Small bowel | MCL: CD5+, CD20+, CD43+
FL: CD10+, CD20+, p27+ | 22 cycles of chemotherapy over 2 years | Complete remission | [7] |
|
|
